Compare Coursera Inc (COUR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Sana Biotechnology Inc — how do they compare? Coursera Inc trades at $5.23 (market cap $1.39B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Coursera Inc is the larger of the two by market cap, and Coursera Inc is more actively traded (9,728,980 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Sana Biotechnology Inc for 23 Days on average.
| COUR | SANA | |
|---|---|---|
Market Cap | $1.39B | $836.71M |
Volume | 9,728,980 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $5.92 |
52-Week Low | $4.64 | $2.68 |
Typical Hold Time | 47 Days | 23 Days |
Enterprise Value | $648.49M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.235, up 2.45% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Revenue has grown steadily from $524M in 2022 to $758M in 2025, though the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights strong institutional interest, including a 137% surge in call option volume (Defense World, 2026-10-01) and the launch of Project Helix, an AI-native learning platform (Business Wire, 2026-09-09).
The stock offers upside to the $7.40 analyst consensus target but faces risks from persistent losses and integration challenges. Positive cash flow and subscriber growth are key strengths, yet profitability remains elusive. Investors should weigh the 52.94% buy rating against high RSI levels and competitive pressures in the edtech sector.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
